Le Lézard
Classified in: Health, Science and technology

Global Biomarker Technologies Market by Product, Technology, Application and Indication - Forecast to 2026 - ResearchAndMarkets.com


The "Biomarker Technologies Market by Product, Technology and Application, and Indication: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

According to this report, the biomarker technologies market accounted for $21,594 million in 2018 is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026.

The key factors that drive the growth of the global biomarker technologies market are rise in prevalence of various diseases such as cancer, autoimmune diseases, and others. The other factors that contribute toward the growth of the market include surge in research related to drug discovery and increase in healthcare expenditure.

However, high initial investments for the discovery of biomarker can hamper the market growth to a certain extent. Whereas, surge in awareness associated with the need of early detection of various diseases such as cancers and high growth potential in emerging economies are anticipated to provide lucrative opportunities in the market during the forecast period.

On the basis of technology, the immunoassay segment was a major revenue contributor in 2018 and is expected to maintain its dominant position throughout the analysis period due to surge in prevalence of various diseases across the globe. For instance, the rise in prevalence of cancer contributes to the growth of biomarker technologies market as biomarkers serve as tools in diagnosis of cancer.

Moreover, other diseases such as diabetes type 1, is highly prevalent worldwide. This factor contributes toward the growth of the biomarker technologies market. In addition, infectious diseases such as AIDS, tuberculosis, and others are also diagnosed using biomarkers. Therefore, the factors above mentioned are responsible for the growth of this segment.

On the other side, next generation sequencing is expected to be the fastest growing segment during the forecast period as this technique is highly advantageous due to its property of differentiating between closely related tumor cells to provide better understanding of the growth of cancer. Moreover, the rise in research related to cancer worldwide is another factor that boosts the growth of this market.

According to product, the consumables segment accounted for the highest market share in 2018, and is anticipated to maintain this trend during the forecast period, as consumables form an important part of biomarker testing. Instrument segment is the fastest growing segment during the forecast period owing to the technological advancements.

In 2018, North America accounted for the major share of biomarker technologies market size and is expected to continue this trend owing to higher number of R&D activities, presence of skilled technicians, and wide availability of technologically advanced biomarker testing instruments and high prevalence of disease such as cancer, infectious diseases, neurological disorders, autoimmune diseases, and others. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period.

The major companies profiled in this report include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., LI-COR, Inc., Merck KGAA, PerkinElmer Inc., QIAGEN, Shimadzu Corporation, and Thermo Fisher Scientific, Inc.

Key Findings of the Biomarker Technologies Market

For more information about this report visit https://www.researchandmarkets.com/r/yt1gyl


These press releases may also interest you

at 01:15
Core One Labs Inc. , , (the "Company" or "Core One") is a research and development company focused on bringing psychedelic medicines to market through the development and production of API grade psychedelic compounds, the advancement of psychedelic...

at 01:05
Regulatory News: Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject® / Injectafer® with sales up 22.8% at CER as a result of improved patient access as COVID-19 restrictions eased in key markets....

at 01:05
Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced...

at 01:00
Diagnos (FRA: 4D4A) is opening clinics and forming distribution partnerships all over the world, including Canada, Spain, Saudi Arabia, Mexico, Europe, Costa Rica and the U.S....

at 01:00
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the first six months of 2021 ended June 30, 2021. The Company will hold an analyst conference call...

at 00:01
In the face of the latest and more contagious variant of COVID-19, Delta, a bipartisan group of leaders and public health experts, in an open letter to CEOs provided by the COVID Collaborative, are calling on private sector employers to require...



News published on 23 october 2019 at 04:10 and distributed by: